{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:28:27Z","timestamp":1789468107601,"version":"build-2803163510"},"reference-count":153,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s00393-024-01596-7","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T12:15:11Z","timestamp":1743768911000},"page":"225-251","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Diagnostik und Therapie der ANCA-assoziierten Vaskulitiden","Diagnosis and treatment of ANCA-associated vasculitis"],"prefix":"10.1007","volume":"84","author":[{"given":"J. U.","family":"Holle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Kubacki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Aries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Hellmich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kernder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Kneitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Lamprecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. H.","family":"Schirmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Berlit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. A.","family":"Bley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bl\u00f6dt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Decker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"de Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Engel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Jordans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Frye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Haubitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Holl-Ulrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"K\u00f6tter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Laudien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Milger-Kneidinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Muche-Borowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"M\u00fcller-Ladner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Ne\u00df","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"N\u00f6lle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Reinhold-Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Ruffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Scheuermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Venhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"von Vietinghoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Wiech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Z\u00e4nker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Moosig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,2]]},"reference":[{"issue":"3","key":"1596_CR1","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/art.41986","volume":"74","author":"JC Robson","year":"2022","unstructured":"Robson\u00a0JC, Grayson\u00a0PC, Ponte\u00a0C, Suppiah\u00a0R, Craven\u00a0A, Judge\u00a0A et\u00a0al (2022) 2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology Classification Criteria for Granulomatosis With Polyangiitis. Arthritis Rheumatol 74(3):393\u2013399","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"1596_CR2","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1002\/art.41983","volume":"74","author":"R Suppiah","year":"2022","unstructured":"Suppiah\u00a0R, Robson\u00a0JC, Grayson\u00a0PC, Ponte\u00a0C, Craven\u00a0A, Khalid\u00a0S et\u00a0al (2022) 2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology Classification Criteria for Microscopic Polyangiitis. Arthritis Rheumatol 74(3):400\u2013406","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"1596_CR3","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1002\/art.41982","volume":"74","author":"PC Grayson","year":"2022","unstructured":"Grayson\u00a0PC, Ponte\u00a0C, Suppiah\u00a0R, Robson\u00a0JC, Craven\u00a0A, Judge\u00a0A et\u00a0al (2022) 2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis With Polyangiitis. Arthritis Rheumatol 74(3):386\u2013392","journal-title":"Arthritis Rheumatol"},{"key":"1596_CR4","doi-asserted-by":"crossref","unstructured":"Hellmich B, Sanchez-Alamo B, Schirmer JH, Berti A, Blockmans D, Cid MC et\u00a0al (2023) EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis","DOI":"10.1136\/ard-2022-223764"},{"issue":"5","key":"1596_CR5","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1136\/ard.2006.062711","volume":"66","author":"B Hellmich","year":"2007","unstructured":"Hellmich\u00a0B, Flossmann\u00a0O, Gross\u00a0WL, Bacon\u00a0P, Cohen-Tervaert\u00a0JW, Guillevin\u00a0L et\u00a0al (2007) EULAR recommendations for conducting clinical studies and\/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 66(5):605\u2013617","journal-title":"Ann Rheum Dis"},{"issue":"21-22","key":"1596_CR6","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s00508-015-0747-1","volume":"128","author":"S Guneyli","year":"2016","unstructured":"Guneyli\u00a0S, Ceylan\u00a0N, Bayraktaroglu\u00a0S, Gucenmez\u00a0S, Aksu\u00a0K, Kocacelebi\u00a0K et\u00a0al (2016) Imaging findings of pulmonary granulomatosis with polyangiitis (Wegener\u2019s granulomatosis): lesions invading the pulmonary fissure, pleura or diaphragm mimicking malignancy. Wien Klin Wochenschr 128(21-22):809\u2013815","journal-title":"Wien Klin Wochenschr"},{"issue":"5","key":"1596_CR7","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1097\/01.rct.0000135280.79012.c7","volume":"28","author":"Y Ando","year":"2004","unstructured":"Ando\u00a0Y, Okada\u00a0F, Matsumoto\u00a0S, Mori\u00a0H (2004) Thoracic manifestation of myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA)-related disease. CT findings in 51\u00a0patients. J\u00a0Comput Assist Tomogr 28(5):710\u2013716","journal-title":"J Comput Assist Tomogr"},{"issue":"10","key":"1596_CR8","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.3899\/jrheum.161224","volume":"44","author":"AJ Mohammad","year":"2017","unstructured":"Mohammad\u00a0AJ, Mortensen\u00a0KH, Babar\u00a0J, Smith\u00a0R, Jones\u00a0RB, Nakagomi\u00a0D et\u00a0al (2017) Pulmonary Involvement in Antineutrophil Cytoplasmic Antibodies (ANCA)-associated Vasculitis: The Influence of ANCA Subtype. J\u00a0Rheumatol 44(10):1458\u20131467","journal-title":"J Rheumatol"},{"issue":"4","key":"1596_CR9","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1136\/annrheumdis-2016-209507","volume":"76","author":"J Damoiseaux","year":"2017","unstructured":"Damoiseaux\u00a0J, Csernok\u00a0E, Rasmussen\u00a0N, Moosig\u00a0F, van Paassen\u00a0P, Baslund\u00a0B et\u00a0al (2017) Detection of antineutrophil cytoplasmic antibodies (ANCAs): a\u00a0multicentre European Vasculitis Study Group (EUVAS) evaluation of the value of indirect immunofluorescence (IIF) versus antigen-specific immunoassays. Ann Rheum Dis 76(4):647\u2013653","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"1596_CR10","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.autrev.2016.03.010","volume":"15","author":"E Csernok","year":"2016","unstructured":"Csernok\u00a0E, Damoiseaux\u00a0J, Rasmussen\u00a0N, Hellmich\u00a0B, van Paassen\u00a0P, Vermeersch\u00a0P et\u00a0al (2016) Evaluation of automated multi-parametric indirect immunofluorescence assays to detect anti-neutrophil cytoplasmic antibodies (ANCA) in granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). Autoimmun Rev 15(7):736\u2013741","journal-title":"Autoimmun Rev"},{"issue":"12","key":"1596_CR11","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.1007\/s10067-019-04736-6","volume":"38","author":"W Zhang","year":"2019","unstructured":"Zhang\u00a0W, Zheng\u00a0Z, Jia\u00a0R, Li\u00a0X, Zuo\u00a0X, Wu\u00a0L et\u00a0al (2019) Evaluation of 12\u00a0different assays for detecting ANCA in Chinese patients with GPA and MPA: a\u00a0multicenter study in China. Clin Rheumatol 38(12):3477\u20133483","journal-title":"Clin Rheumatol"},{"issue":"1","key":"1596_CR12","doi-asserted-by":"publisher","first-page":"102716","DOI":"10.1016\/j.autrev.2020.102716","volume":"20","author":"NAD Guchelaar","year":"2021","unstructured":"Guchelaar\u00a0NAD, Waling\u00a0MM, Adhin\u00a0AA, van Daele\u00a0PLA, Schreurs\u00a0MWJ, Rombach\u00a0SM (2021) The value of anti-neutrophil cytoplasmic antibodies (ANCA) testing for the diagnosis of ANCA-associated vasculitis, a\u00a0systematic review and meta-analysis. Autoimmun Rev 20(1):102716","journal-title":"Autoimmun Rev"},{"issue":"6","key":"1596_CR13","doi-asserted-by":"publisher","first-page":"103100","DOI":"10.1016\/j.autrev.2022.103100","volume":"21","author":"BS Walker","year":"2022","unstructured":"Walker\u00a0BS, Peterson\u00a0LK, Koening\u00a0C, White\u00a0SK, Schmidt\u00a0RL, Tebo\u00a0AE (2022) Performance of MPO-ANCA and PR3-ANCA immunoassays for the stratification of specific ANCA-associated vasculitis: A\u00a0systematic review and meta-analysis. Autoimmun Rev 21(6):103100","journal-title":"Autoimmun Rev"},{"issue":"11","key":"1596_CR14","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/nrrheum.2017.140","volume":"13","author":"X Bossuyt","year":"2017","unstructured":"Bossuyt\u00a0X, Cohen Tervaert\u00a0JW, Arimura\u00a0Y, Blockmans\u00a0D, Flores-Suarez\u00a0LF, Guillevin\u00a0L et\u00a0al (2017) Position paper: Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. Nat Rev Rheumatol 13(11):683\u2013692","journal-title":"Nat Rev Rheumatol"},{"key":"1596_CR15","doi-asserted-by":"crossref","unstructured":"Moiseev S, Bossuyt X, Arimura Y, Blockmans D, Csernok E, Damoiseaux J et\u00a0al (2020) International Consensus on ANCA Testing in Eosinophilic Granulomatosis with Polyangiitis. Am J Respir Crit Care Med","DOI":"10.1164\/rccm.202005-1628SO"},{"issue":"1","key":"1596_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","volume":"65","author":"JC Jennette","year":"2013","unstructured":"Jennette\u00a0JC, Falk\u00a0RJ, Bacon\u00a0PA, Basu\u00a0N, Cid\u00a0MC, Ferrario\u00a0F et\u00a0al (2013) 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65(1):1\u201311","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1596_CR17","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.jaip.2020.07.038","volume":"9","author":"HC Chang","year":"2021","unstructured":"Chang\u00a0HC, Chou\u00a0PC, Lai\u00a0CY, Tsai\u00a0HH (2021) Antineutrophil Cytoplasmic Antibodies and Organ-Specific Manifestations in Eosinophilic Granulomatosis with Polyangiitis: A\u00a0Systematic Review and Meta-Analysis. J\u00a0Allergy Clin Immunol Pract 9(1):445\u201352 e6","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"1596_CR18","doi-asserted-by":"publisher","first-page":"216","DOI":"10.3899\/jrheum.160005","volume":"44","author":"S Furuta","year":"2017","unstructured":"Furuta\u00a0S, Chaudhry\u00a0AN, Arimura\u00a0Y, Dobashi\u00a0H, Fujimoto\u00a0S, Homma\u00a0S et\u00a0al (2017) Comparison of the Phenotype and Outcome of Granulomatosis with Polyangiitis Between UK and Japanese Cohorts. J\u00a0Rheumatol 44(2):216\u2013222","journal-title":"J Rheumatol"},{"issue":"11","key":"1596_CR19","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.3899\/jrheum.121473","volume":"40","author":"PC Grayson","year":"2013","unstructured":"Grayson\u00a0PC, Cuthbertson\u00a0D, Carette\u00a0S, Hoffman\u00a0GS, Khalidi\u00a0NA, Koening\u00a0CL et\u00a0al (2013) New features of disease after diagnosis in 6 forms of systemic vasculitis. J\u00a0Rheumatol 40(11):1905\u20131912","journal-title":"J Rheumatol"},{"key":"1596_CR20","doi-asserted-by":"crossref","unstructured":"Puechal X, Iudici M, Pagnoux C, Cohen P, Hamidou M, Aouba A et\u00a0al (2022) Comparative study of granulomatosis with polyangiitis subsets according to ANCA status: data from the French Vasculitis Study Group Registry. RMD Open 8(1)","DOI":"10.1136\/rmdopen-2021-002160"},{"issue":"8","key":"1596_CR21","doi-asserted-by":"publisher","first-page":"e6083","DOI":"10.1097\/MD.0000000000006083","volume":"96","author":"R Solans-Laque","year":"2017","unstructured":"Solans-Laque\u00a0R, Fraile\u00a0G, Rodriguez-Carballeira\u00a0M, Caminal\u00a0L, Castillo\u00a0MJ, Martinez-Valle\u00a0F et\u00a0al (2017) Clinical characteristics and outcome of Spanish patients with ANCA-associated vasculitides: Impact of the vasculitis type, ANCA specificity, and treatment on mortality and morbidity. Medicine 96(8):e6083","journal-title":"Medicine"},{"issue":"1","key":"1596_CR22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.berh.2018.10.001","volume":"32","author":"C Ponte","year":"2018","unstructured":"Ponte\u00a0C, Agueda\u00a0AF, Luqmani\u00a0RA (2018) Clinical features and structured clinical evaluation of vasculitis. Best Pract Res Clin Rheumatol 32(1):31\u201351","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"2","key":"1596_CR23","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa0909905","volume":"363","author":"JHMP Stone","year":"2010","unstructured":"Stone\u00a0JHMP, Spiera\u00a0R, Seo\u00a0P, Langford\u00a0CA, Hoffman\u00a0GS, Kallenberg\u00a0CG, St Clair\u00a0EW, Turkiewicz\u00a0A, Tchao\u00a0NK, Webber\u00a0L, Ding\u00a0L, Sejismundo\u00a0LP, Mieras\u00a0K, Weitzenkamp\u00a0D, Ikle\u00a0D, Seyfert-Margolis\u00a0V, Mueller\u00a0M, Brunetta\u00a0P, Allen\u00a0NB, Fervenza\u00a0FC, Geetha\u00a0D, Keogh\u00a0KA, Kissin\u00a0EY, Monach\u00a0PA, Peikert\u00a0T, Stegeman\u00a0C, Ytterberg\u00a0SR, Specks\u00a0U (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N\u00a0Engl J Med 363(2):221\u2013232","journal-title":"N Engl J Med"},{"issue":"5","key":"1596_CR24","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMoa1213277","volume":"369","author":"U Specks","year":"2013","unstructured":"Specks\u00a0U, Merkel\u00a0PA, Seo\u00a0P, Spiera\u00a0R, Langford\u00a0CA, Hoffman\u00a0GS et\u00a0al (2013) Efficacy of remission-induction regimens for ANCA-associated vasculitis. N\u00a0Engl J Med 369(5):417\u2013427","journal-title":"N Engl J Med"},{"key":"1596_CR25","doi-asserted-by":"publisher","first-page":"670","DOI":"10.7326\/0003-4819-150-10-200905190-00004","volume":"150","author":"KHL de Groot","year":"2009","unstructured":"de Groot\u00a0KHL, Jayne\u00a0DRW, Suarez\u00a0FLF, Gregorini\u00a0G, Gross\u00a0WL et\u00a0al (2009) Pulse versus daily oral cyclophosphamide for induction of remission in Antineutrophil cytoplasmic-antibody-associated vasculitis. Ann Intern Med 150:670\u2013680","journal-title":"Ann Intern Med"},{"key":"1596_CR26","first-page":"CD003232","volume":"1","author":"GD Walters","year":"2020","unstructured":"Walters\u00a0GD, Willis\u00a0NS, Cooper\u00a0TE, Craig\u00a0JC (2020) Interventions for renal vasculitis in adults. Cochrane Database Syst Rev 1:CD3232","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"1596_CR27","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00393-017-0394-1","volume":"76","author":"JH Schirmer","year":"2017","unstructured":"Schirmer\u00a0JH, Aries\u00a0PM, de Groot\u00a0K, Hellmich\u00a0B, Holle\u00a0JU, Kneitz\u00a0C et\u00a0al (2017) S1 guidelines Diagnostics and treatment of ANCA-associated vasculitis. Z\u00a0Rheumatol 76(3):77\u2013104","journal-title":"Z Rheumatol"},{"issue":"3","key":"1596_CR28","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa0909169","volume":"363","author":"RBTJW Jones","year":"2010","unstructured":"Jones\u00a0RBTJW, Hauser\u00a0T, Luqmani\u00a0R, Morgan\u00a0MD, Peh\u00a0CA, Savage\u00a0CO, Segelmark\u00a0M, Tesar\u00a0V, vsn Paassen\u00a0P, Walsh\u00a0D, Westman\u00a0K, Jayne\u00a0DR, European Vasculitis Study Group (2010) Rituxmab versus cyclophosphamide in ANCA-associated renal vasculitis. N\u00a0Engl J Med 363(3):211\u2013220","journal-title":"N Engl J Med"},{"issue":"6","key":"1596_CR29","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1136\/annrheumdis-2011-200477","volume":"71","author":"L Harper","year":"2012","unstructured":"Harper\u00a0L, Morgan\u00a0MD, Walsh\u00a0M, Hoglund\u00a0P, Westman\u00a0K, Flossmann\u00a0O et\u00a0al (2012) Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis 71(6):955\u2013960","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"1596_CR30","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/acr2.11274","volume":"3","author":"V Benard","year":"2021","unstructured":"Benard\u00a0V, Farhat\u00a0C, Zarandi-Nowroozi\u00a0M, Durand\u00a0M, Charles\u00a0P, Puechal\u00a0X et\u00a0al (2021) Comparison of Two Rituximab Induction Regimens for Antineutrophil Cytoplasm Antibody-Associated Vasculitis: Systematic Review and Meta-Analysis. ACR Open Rheumatol 3(7):484\u2013494","journal-title":"ACR Open Rheumatol"},{"issue":"10","key":"1596_CR31","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1002\/1529-0131(199810)41:10<1835::AID-ART16>3.0.CO;2-Q","volume":"41","author":"M Haubitz","year":"1998","unstructured":"Haubitz\u00a0M, Schellong\u00a0S, Gobel\u00a0U, Schurek\u00a0HJ, Schaumann\u00a0D, Koch\u00a0KM et\u00a0al (1998) Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a\u00a0prospective, randomized study. Arthritis Rheum 41(10):1835\u20131844","journal-title":"Arthritis Rheum"},{"issue":"7","key":"1596_CR32","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa2023386","volume":"384","author":"DRW Jayne","year":"2021","unstructured":"Jayne\u00a0DRW, Merkel\u00a0PA, Schall\u00a0TJ, Bekker\u00a0P, Group AS (2021) Avacopan for the Treatment of ANCA-Associated Vasculitis. N\u00a0Engl J Med 384(7):599\u2013609","journal-title":"N Engl J Med"},{"issue":"8","key":"1596_CR33","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1002\/art.21142","volume":"52","author":"K De Groot","year":"2005","unstructured":"De Groot\u00a0K, Rasmussen\u00a0N, Bacon\u00a0PA, Tervaert\u00a0JW, Feighery\u00a0C, Gregorini\u00a0G et\u00a0al (2005) Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52(8):2461\u20132469","journal-title":"Arthritis Rheum"},{"issue":"10","key":"1596_CR34","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1002\/art.34547","volume":"64","author":"M Faurschou","year":"2012","unstructured":"Faurschou\u00a0M, Westman\u00a0K, Rasmussen\u00a0N, de Groot\u00a0K, Flossmann\u00a0O, Hoglund\u00a0P et\u00a0al (2012) Brief Report: long-term outcome of a\u00a0randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 64(10):3472\u20133477","journal-title":"Arthritis Rheum"},{"issue":"21","key":"1596_CR35","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1001\/jama.2021.6615","volume":"325","author":"S Furuta","year":"2021","unstructured":"Furuta\u00a0S, Nakagomi\u00a0D, Kobayashi\u00a0Y, Hiraguri\u00a0M, Sugiyama\u00a0T, Amano\u00a0K et\u00a0al (2021) Effect of reduced-dose vs high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: a\u00a0randomized clinical trial. JAMA 325(21):2178\u20132187","journal-title":"JAMA"},{"issue":"9","key":"1596_CR36","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1136\/annrheumdis-2019-216863","volume":"79","author":"RM Smith","year":"2020","unstructured":"Smith\u00a0RM, Jones\u00a0RB, Specks\u00a0U, Bond\u00a0S, Nodale\u00a0M, Aljayyousi\u00a0R et\u00a0al (2020) Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. Ann Rheum Dis 79(9):1243\u20131249","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1596_CR37","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1136\/annrheumdis-2018-214245","volume":"78","author":"RB Jones","year":"2019","unstructured":"Jones\u00a0RB, Hiemstra\u00a0TF, Ballarin\u00a0J, Blockmans\u00a0DE, Brogan\u00a0P, Bruchfeld\u00a0A et\u00a0al (2019) Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a\u00a0randomised, non-inferiority trial. Ann Rheum Dis 78(3):399\u2013405","journal-title":"Ann Rheum Dis"},{"key":"1596_CR38","unstructured":"Smith RM, Jones RB, Specks U, Bond S, Nodale M, Al-Jayyousi R et\u00a0al (2023) Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial. Ann Rheum Dis"},{"issue":"7","key":"1596_CR39","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1056\/NEJMoa1803537","volume":"382","author":"M Walsh","year":"2020","unstructured":"Walsh\u00a0M, Merkel\u00a0PA, Peh\u00a0CA, Szpirt\u00a0WM, Puechal\u00a0X, Fujimoto\u00a0S et\u00a0al (2020) Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. N\u00a0Engl J Med 382(7):622\u2013631","journal-title":"N Engl J Med"},{"issue":"2","key":"1596_CR40","doi-asserted-by":"publisher","first-page":"e050507","DOI":"10.1136\/bmjopen-2021-050507","volume":"12","author":"Y Xiao","year":"2022","unstructured":"Xiao\u00a0Y, Guyatt\u00a0G, Zeng\u00a0L, Rw\u00a0JD, P\u00a0AM, Ac Siemieniuk\u00a0R et\u00a0al (2022) Comparative efficacy and safety of alternative glucocorticoids regimens in patients with ANCA-associated vasculitis: a\u00a0systematic review. BMJ Open 12(2):e50507","journal-title":"BMJ Open"},{"issue":"4","key":"1596_CR41","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.ekir.2023.01.039","volume":"8","author":"FB Cortazar","year":"2023","unstructured":"Cortazar\u00a0FB, Niles\u00a0JL, Jayne\u00a0DRW, Merkel\u00a0PA, Bruchfeld\u00a0A, Yue\u00a0H et\u00a0al (2023) Renal recovery for patients with ANCA-associated vasculitis and low eGFR in the ADVOCATE trial of avacopan. Kidney Int Rep 8(4):860\u2013870","journal-title":"Kidney Int Rep"},{"key":"1596_CR42","doi-asserted-by":"publisher","first-page":"e064604","DOI":"10.1136\/bmj-2021-064604","volume":"376","author":"M Walsh","year":"2022","unstructured":"Walsh\u00a0M, Collister\u00a0D, Zeng\u00a0L, Merkel\u00a0PA, Pusey\u00a0CD, Guyatt\u00a0G et\u00a0al (2022) The effects of plasma exchange in patients with ANCA-associated vasculitis: an updated systematic review and meta-analysis. BMJ 376:e64604","journal-title":"BMJ"},{"issue":"8","key":"1596_CR43","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1136\/annrheumdis-2017-212768","volume":"77","author":"B Terrier","year":"2018","unstructured":"Terrier\u00a0B, Pagnoux\u00a0C, Perrodeau\u00a0E, Karras\u00a0A, Khouatra\u00a0C, Aumaitre\u00a0O et\u00a0al (2018) Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides. Ann Rheum Dis 77(8):1150\u20131156","journal-title":"Ann Rheum Dis"},{"issue":"19","key":"1596_CR44","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","volume":"371","author":"L Guillevin","year":"2014","unstructured":"Guillevin\u00a0L, Pagnoux\u00a0C, Karras\u00a0A, Khouatra\u00a0C, Aumaitre\u00a0O, Cohen\u00a0P et\u00a0al (2014) Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N\u00a0Engl J Med 371(19):1771\u20131780","journal-title":"N Engl J Med"},{"key":"1596_CR45","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa020286","volume":"349","author":"DRN Jayne","year":"2003","unstructured":"Jayne\u00a0DRN, Andrassy\u00a0K, Bacon\u00a0P (2003) Cohen Tervaert JW Dadonien\u00e9 Jet\u00a0al. A\u00a0randomised trial of maintenance for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N\u00a0Engl J Med 349:36\u201344","journal-title":"N Engl J Med"},{"key":"1596_CR46","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1056\/NEJMoa0802311","volume":"359","author":"CMA Pagnoux","year":"2008","unstructured":"Pagnoux\u00a0CMA, Hamidou\u00a0MA, Boffa\u00a0JJ, Ruivard\u00a0M, Ducroix\u00a0JP et\u00a0al (2008) Azathioprine or Methotrexate maintenance for ANCA-associated vasculitis. N\u00a0Engl J Med 359:2790\u20132803","journal-title":"N Engl J Med"},{"issue":"3","key":"1596_CR47","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1002\/art.39450","volume":"68","author":"X Puechal","year":"2016","unstructured":"Puechal\u00a0X, Pagnoux\u00a0C, Perrodeau\u00a0E, Hamidou\u00a0M, Boffa\u00a0JJ, Kyndt\u00a0X et\u00a0al (2016) Long-Term Outcomes Among Participants in the WEGENT Trial of Remission-Maintenance Therapy for Granulomatosis With Polyangiitis (Wegener\u2019s) or Microscopic Polyangiitis. Arthritis Rheumatol 68(3):690\u2013701","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"1596_CR48","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.ekir.2022.02.020","volume":"7","author":"I Bellos","year":"2022","unstructured":"Bellos\u00a0I, Boletis\u00a0I, Lionaki\u00a0S (2022) A\u00a0Meta-Analysis of the Safety and Efficacy of Maintenance Therapies for Antineutrophil Cytoplasmic Antibody Small-Vessel Vasculitis. Kidney Int Rep 7(5):1074\u20131083","journal-title":"Kidney Int Rep"},{"issue":"10","key":"1596_CR49","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.1093\/rheumatology\/kez621","volume":"59","author":"P Charles","year":"2020","unstructured":"Charles\u00a0P, Dechartres\u00a0A, Terrier\u00a0B, Cohen\u00a0P, Faguer\u00a0S, Huart\u00a0A et\u00a0al (2020) Reducing the initial number of rituximab maintenance-therapy infusions for ANCA-associated vasculitides: randomized-trial post-hoc analysis. Rheumatology 59(10):2970\u20132975","journal-title":"Rheumatology"},{"issue":"8","key":"1596_CR50","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1136\/annrheumdis-2017-212878","volume":"77","author":"P Charles","year":"2018","unstructured":"Charles\u00a0P, Terrier\u00a0B, Perrodeau\u00a0E, Cohen\u00a0P, Faguer\u00a0S, Huart\u00a0A et\u00a0al (2018) Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a\u00a0multicentre, randomised controlled, phase\u00a0III trial (MAINRITSAN2). Ann Rheum Dis 77(8):1143\u20131149","journal-title":"Ann Rheum Dis"},{"issue":"21","key":"1596_CR51","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1001\/jama.2010.1658","volume":"304","author":"TF Hiemstra","year":"2010","unstructured":"Hiemstra\u00a0TF, Walsh\u00a0M, Mahr\u00a0A, Savage\u00a0CO, de Groot\u00a0K, Harper\u00a0L et\u00a0al (2010) Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a\u00a0randomized controlled trial. JAMA 304(21):2381\u20132388","journal-title":"JAMA"},{"issue":"7","key":"1596_CR52","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1093\/rheumatology\/kem029","volume":"46","author":"C Metzler","year":"2007","unstructured":"Metzler\u00a0C, Miehle\u00a0N, Manger\u00a0K, Iking-Konert\u00a0C, de Groot\u00a0K, Hellmich\u00a0B et\u00a0al (2007) Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener\u2019s granulomatosis. Rheumatology 46(7):1087\u20131091","journal-title":"Rheumatology"},{"issue":"11","key":"1596_CR53","doi-asserted-by":"publisher","first-page":"948","DOI":"10.7326\/L20-1199","volume":"173","author":"P Charles","year":"2020","unstructured":"Charles\u00a0P, Guillevin\u00a0L (2020) Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Ann Intern Med 173(11):948","journal-title":"Ann Intern Med"},{"issue":"10","key":"1596_CR54","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1136\/annrheumdis-2017-211123","volume":"76","author":"A Karras","year":"2017","unstructured":"Karras\u00a0A, Pagnoux\u00a0C, Haubitz\u00a0M, Groot\u00a0K, Puechal\u00a0X, Tervaert\u00a0JWC et\u00a0al (2017) Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis. Ann Rheum Dis 76(10):1662\u20131668","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1596_CR55","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2215\/CJN.06460622","volume":"18","author":"M Casal Moura","year":"2023","unstructured":"Casal Moura\u00a0M, Specks\u00a0U, Tehranian\u00a0S, Sethi\u00a0S, Zubidat\u00a0D, Nardelli\u00a0L et\u00a0al (2023) Maintenance of remission and risk of relapse in myeloperoxidase-positive ANCA-associated vasculitis with kidney involvement. Clin J Am Soc Nephrol 18(1):47\u201359","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"1596_CR56","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1002\/art.40538","volume":"70","author":"H Watanabe","year":"2018","unstructured":"Watanabe\u00a0H, Sada\u00a0KE, Matsumoto\u00a0Y, Harigai\u00a0M, Amano\u00a0K, Dobashi\u00a0H et\u00a0al (2018) Association Between Reappearance of Myeloperoxidase-Antineutrophil Cytoplasmic Antibody and Relapse in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Subgroup Analysis of Nationwide Prospective Cohort Studies. Arthritis Rheumatol 70(10):1626\u20131633","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"1596_CR57","doi-asserted-by":"publisher","first-page":"179","DOI":"10.7326\/M19-3827","volume":"173","author":"P Charles","year":"2020","unstructured":"Charles\u00a0P, Perrodeau\u00a0E, Samson\u00a0M, Bonnotte\u00a0B, Neel\u00a0A, Agard\u00a0C et\u00a0al (2020) Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A\u00a0Randomized Trial. Ann Intern Med 173(3):179\u2013187","journal-title":"Ann Intern Med"},{"issue":"9","key":"1596_CR58","doi-asserted-by":"publisher","first-page":"621","DOI":"10.7326\/0003-4819-143-9-200511010-00005","volume":"143","author":"SL Hogan","year":"2005","unstructured":"Hogan\u00a0SL, Falk\u00a0RJ, Chin\u00a0H, Cai\u00a0J, Jennette\u00a0CE, Jennette\u00a0JC et\u00a0al (2005) Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med 143(9):621\u2013631","journal-title":"Ann Intern Med"},{"issue":"7","key":"1596_CR59","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1002\/art.39637","volume":"68","author":"LA Fussner","year":"2016","unstructured":"Fussner\u00a0LA, Hummel\u00a0AM, Schroeder\u00a0DR, Silva\u00a0F, Cartin-Ceba\u00a0R, Snyder\u00a0MR et\u00a0al (2016) Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3. Arthritis Rheumatol 68(7):1700\u20131710","journal-title":"Arthritis Rheumatol"},{"key":"1596_CR60","doi-asserted-by":"publisher","first-page":"844112","DOI":"10.3389\/fmed.2022.844112","volume":"9","author":"A Al-Soudi","year":"2022","unstructured":"Al-Soudi\u00a0A, Vegting\u00a0Y, Klarenbeek\u00a0PL, Hilhorst\u00a0ML (2022) Do Relapses Follow ANCA Rises? A\u00a0Systematic Review and Meta-Analysis on the Value of Serial ANCA Level Evaluation. Front Med 9:844112","journal-title":"Front Med"},{"issue":"1","key":"1596_CR61","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13075-017-1321-1","volume":"19","author":"MD Morgan","year":"2017","unstructured":"Morgan\u00a0MD, Szeto\u00a0M, Walsh\u00a0M, Jayne\u00a0D, Westman\u00a0K, Rasmussen\u00a0N et\u00a0al (2017) Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a\u00a0reduced risk of relapse. Arthritis Res Ther 19(1):129","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"1596_CR62","doi-asserted-by":"publisher","first-page":"3770","DOI":"10.1002\/art.34584","volume":"64","author":"R Cartin-Ceba","year":"2012","unstructured":"Cartin-Ceba\u00a0R, Golbin\u00a0JM, Keogh\u00a0KA, Peikert\u00a0T, Sanchez-Menendez\u00a0M, Ytterberg\u00a0SR et\u00a0al (2012) Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener\u2019s): ten-year experience at a\u00a0single center. Arthritis Rheum 64(11):3770\u20133778","journal-title":"Arthritis Rheum"},{"issue":"3","key":"1596_CR63","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1136\/ard.2011.153601","volume":"71","author":"JU Holle","year":"2012","unstructured":"Holle\u00a0JU, Dubrau\u00a0C, Herlyn\u00a0K, Heller\u00a0M, Ambrosch\u00a0P, Noelle\u00a0B et\u00a0al (2012) Rituximab for refractory granulomatosis with polyangiitis (Wegener\u2019s granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations. Ann Rheum Dis 71(3):327\u2013333","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"1596_CR64","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1016\/j.ophtha.2011.06.009","volume":"118","author":"L Joshi","year":"2011","unstructured":"Joshi\u00a0L, Lightman\u00a0SL, Salama\u00a0AD, Shirodkar\u00a0AL, Pusey\u00a0CD, Taylor\u00a0SR (2011) Rituximab in refractory ophthalmic Wegener\u2019s granulomatosis: PR3 titers may predict relapse, but repeat treatment can be effective. Ophthalmology 118(12):2498\u20132503","journal-title":"Ophthalmology"},{"issue":"2","key":"1596_CR65","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1164\/rccm.200507-1144OC","volume":"173","author":"KA Keogh","year":"2006","unstructured":"Keogh\u00a0KA, Ytterberg\u00a0SR, Fervenza\u00a0FC, Carlson\u00a0KA, Schroeder\u00a0DR, Specks\u00a0U (2006) Rituximab for refractory Wegener\u2019s granulomatosis: report of a\u00a0prospective, open-label pilot trial. Am J Respir Crit Care Med 173(2):180\u2013187","journal-title":"Am J Respir Crit Care Med"},{"issue":"3 Suppl 49","key":"1596_CR66","first-page":"S67","volume":"26","author":"D Roccatello","year":"2008","unstructured":"Roccatello\u00a0D, Baldovino\u00a0S, Alpa\u00a0M, Rossi\u00a0D, Napoli\u00a0F, Naretto\u00a0C et\u00a0al (2008) Effects of anti-CD20 monoclonal antibody as a\u00a0rescue treatment for ANCA-associated idiopathic systemic vasculitis with or without overt renal involvement. Clin Exp Rheumatol 26(3 Suppl 49):S67\u2013S71","journal-title":"Clin Exp Rheumatol"},{"issue":"11","key":"1596_CR67","doi-asserted-by":"publisher","first-page":"3662","DOI":"10.1093\/rheumatology\/kead098","volume":"62","author":"B Sorin","year":"2023","unstructured":"Sorin\u00a0B, Iudici\u00a0M, Guerry\u00a0MJ, Samson\u00a0M, Bielefeld\u00a0P, Maillet\u00a0T et\u00a0al (2023) Induction failure in granulomatosis with polyangiitis: a\u00a0nationwide case-control study of risk factors and outcomes. Rheumatology 62(11):3662\u20133671","journal-title":"Rheumatology"},{"issue":"12","key":"1596_CR68","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1136\/ard.2010.131953","volume":"69","author":"R Seror","year":"2010","unstructured":"Seror\u00a0R, Pagnoux\u00a0C, Ruivard\u00a0M, Landru\u00a0I, Wahl\u00a0D, Riviere\u00a0S et\u00a0al (2010) Treatment strategies and outcome of induction-refractory Wegener\u2019s granulomatosis or microscopic polyangiitis: analysis of 32\u00a0patients with first-line induction-refractory disease in the WEGENT trial. Ann Rheum Dis 69(12):2125\u20132130","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"1596_CR69","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1093\/qjmed\/93.7.433","volume":"93","author":"DRCH Jayne","year":"2000","unstructured":"Jayne\u00a0DRCH, Adu\u00a0D, Misbah\u00a0S, O\u2019Donogue\u00a0D, Scott\u00a0D, Lockwood\u00a0CM (2000) Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. Qjm 93(7):433\u2013439","journal-title":"Qjm"},{"issue":"5","key":"1596_CR70","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1078\/0171-2985-00197","volume":"206","author":"O Arbach","year":"2002","unstructured":"Arbach\u00a0O, Gross\u00a0WL, Gause\u00a0A (2002) Treatment of refractory Churg-Strauss-Syndrome (CSS) by TNF-alpha blockade. Immunobiology 206(5):496\u2013501","journal-title":"Immunobiology"},{"issue":"9","key":"1596_CR71","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1136\/ard.2007.083584","volume":"67","author":"L Josselin","year":"2008","unstructured":"Josselin\u00a0L, Mahr\u00a0A, Cohen\u00a0P, Pagnoux\u00a0C, Guaydier-Souquieres\u00a0G, Hayem\u00a0G et\u00a0al (2008) Infliximab efficacy and safety against refractory systemic necrotising vasculitides: long-term follow-up of 15\u00a0patients. Ann Rheum Dis 67(9):1343\u20131346","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"1596_CR72","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1093\/rheumatology\/41.11.1303","volume":"41","author":"P Lamprecht","year":"2002","unstructured":"Lamprecht\u00a0P, Voswinkel\u00a0J, Lilienthal\u00a0T, Nolle\u00a0B, Heller\u00a0M, Gross\u00a0WL et\u00a0al (2002) Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener\u2019s granulomatosis. Rheumatology 41(11):1303\u20131307","journal-title":"Rheumatology"},{"issue":"1 Suppl 64","key":"1596_CR73","first-page":"S63","volume":"29","author":"M de Menthon","year":"2011","unstructured":"de Menthon\u00a0M, Cohen\u00a0P, Pagnoux\u00a0C, Buchler\u00a0M, Sibilia\u00a0J, Detree\u00a0F et\u00a0al (2011) Infliximab or rituximab for refractory Wegener\u2019s granulomatosis: long-term follow up. A\u00a0prospective randomised multicentre study on 17\u00a0patients. Clin Exp Rheumatol 29(1 Suppl 64):S63\u2013S71","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"1596_CR74","doi-asserted-by":"publisher","first-page":"c89","DOI":"10.1159\/000319655","volume":"117","author":"MD Morgan","year":"2011","unstructured":"Morgan\u00a0MD, Drayson\u00a0MT, Savage\u00a0CO, Harper\u00a0L (2011) Addition of infliximab to standard therapy for ANCA-associated vasculitis. Nephron Clin Pract 117(2):c89\u2013c97","journal-title":"Nephron Clin Pract"},{"issue":"4","key":"1596_CR75","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1111\/j.1523-1755.2004.00534.x","volume":"65","author":"WH Schmitt","year":"2004","unstructured":"Schmitt\u00a0WH, Hagen\u00a0EC, Neumann\u00a0I, Nowack\u00a0R, Flores-Suarez\u00a0LF, van der Woude\u00a0FJ et\u00a0al (2004) Treatment of refractory Wegener\u2019s granulomatosis with antithymocyte globulin (ATG): an open study in 15\u00a0patients. Kidney Int 65(4):1440\u20131448","journal-title":"Kidney Int"},{"issue":"12","key":"1596_CR76","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1093\/ndt\/gfi117","volume":"20","author":"MS Joy","year":"2005","unstructured":"Joy\u00a0MS, Hogan\u00a0SL, Jennette\u00a0JC, Falk\u00a0RJ, Nachman\u00a0PH (2005) A\u00a0pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. Nephrol Dial Transplant 20(12):2725\u20132732","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"1596_CR77","doi-asserted-by":"publisher","first-page":"445","DOI":"10.2215\/CJN.06010809","volume":"5","author":"F Silva","year":"2010","unstructured":"Silva\u00a0F, Specks\u00a0U, Kalra\u00a0S, Hogan\u00a0MC, Leung\u00a0N, Sethi\u00a0S et\u00a0al (2010) Mycophenolate mofetil for induction and maintenance of remission in microscopic polyangiitis with mild to moderate renal involvement\u2014a prospective, open-label pilot trial. Clin J Am Soc Nephrol 5(3):445\u2013453","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"1596_CR78","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1136\/ard.2006.060301","volume":"66","author":"PM Stassen","year":"2007","unstructured":"Stassen\u00a0PM, Tervaert\u00a0JW, Stegeman\u00a0CA (2007) Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide. Ann Rheum Dis 66(6):798\u2013802","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1596_CR79","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13075-022-02761-6","volume":"24","author":"S Gopaluni","year":"2022","unstructured":"Gopaluni\u00a0S, Smith\u00a0R, Goymer\u00a0D, Cahill\u00a0H, Broadhurst\u00a0E, Wallin\u00a0E et\u00a0al (2022) Alemtuzumab for refractory primary systemic vasculitis\u2014a randomised controlled dose ranging clinical trial of efficacy and safety (ALEVIATE). Arthritis Res Ther 24(1):81","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"1596_CR80","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1136\/ard.2007.081661","volume":"67","author":"M Walsh","year":"2008","unstructured":"Walsh\u00a0M, Chaudhry\u00a0A, Jayne\u00a0D (2008) Long-term follow-up of relapsing\/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H). Ann Rheum Dis 67(9):1322\u20131327","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"1596_CR81","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.autrev.2011.04.028","volume":"10","author":"GJ Pons-Estel","year":"2011","unstructured":"Pons-Estel\u00a0GJ, Salerni\u00a0GE, Serrano\u00a0RM, Gomez-Puerta\u00a0JA, Plasin\u00a0MA, Aldasoro\u00a0E et\u00a0al (2011) Therapeutic plasma exchange for the management of refractory systemic autoimmune diseases: report of 31\u00a0cases and review of the literature. Autoimmun Rev 10(11):679\u2013684","journal-title":"Autoimmun Rev"},{"issue":"1 Suppl 57","key":"1596_CR82","first-page":"67","volume":"28","author":"JP Bremer","year":"2010","unstructured":"Bremer\u00a0JP, Ullrich\u00a0S, Laudien\u00a0M, Gross\u00a0WL, Lamprecht\u00a0P (2010) Methotrexate plus leflunomide for the treatment of relapsingWegener\u2019s granulomatosis. A\u00a0retrospective uncontrolled study. Clin Exp Rheumatol 28(1 Suppl 57):67\u201371","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"1596_CR83","doi-asserted-by":"publisher","first-page":"114","DOI":"10.55563\/clinexprheumatol\/ve38dj","volume":"39 Suppl 129","author":"N Mustapha","year":"2021","unstructured":"Mustapha\u00a0N, Barra\u00a0L, Carette\u00a0S, Cuthbertson\u00a0D, Khalidi\u00a0NA, Koening\u00a0CL et\u00a0al (2021) Efficacy of leflunomide in the treatment of vasculitis. Clin Exp Rheumatol 39 Suppl 129(2):114\u2013118","journal-title":"Clin Exp Rheumatol"},{"issue":"9","key":"1596_CR84","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.1093\/rheumatology\/keab916","volume":"61","author":"NA Amudala","year":"2022","unstructured":"Amudala\u00a0NA, Boukhlal\u00a0S, Sheridan\u00a0B, Langford\u00a0CA, Geara\u00a0A, Merkel\u00a0PA et\u00a0al (2022) Obinutuzumab as treatment for ANCA-associated vasculitis. Rheumatology 61(9):3814\u20133817","journal-title":"Rheumatology"},{"key":"1596_CR85","doi-asserted-by":"crossref","unstructured":"Ostendorf L, Burns M, Wagner DL, Enghard P, Amann K, Mei H et\u00a0al (2023) Daratumumab for the treatment of refractory ANCA-associated vasculitis. RMD Open 9(1)","DOI":"10.1136\/rmdopen-2022-002742"},{"issue":"6","key":"1596_CR86","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.kint.2021.09.020","volume":"100","author":"P Enghard","year":"2021","unstructured":"Enghard\u00a0P, Zickler\u00a0D, Sonnemann\u00a0J, Schneider\u00a0W, Lurje\u00a0G, Elezkurtaj\u00a0S et\u00a0al (2021) Imlifidase as novel treatment strategy in anti-neutrophil cytoplasmic antibody-induced pulmonary-renal syndrome. Kidney Int 100(6):1344\u20131345","journal-title":"Kidney Int"},{"issue":"4","key":"1596_CR87","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/art.22679","volume":"57","author":"P Cohen","year":"2007","unstructured":"Cohen\u00a0P, Pagnoux\u00a0C, Mahr\u00a0A, Arene\u00a0JP, Mouthon\u00a0L, Le Guern\u00a0V et\u00a0al (2007) Churg-Strauss syndrome with poor-prognosis factors: A\u00a0prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Rheum 57(4):686\u2013693","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1596_CR88","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/00005792-199601000-00003","volume":"75","author":"L Guillevin","year":"1996","unstructured":"Guillevin\u00a0L, Lhote\u00a0F, Gayraud\u00a0M, Cohen\u00a0P, Jarrousse\u00a0B, Lortholary\u00a0O et\u00a0al (1996) Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A\u00a0prospective study in 342 patients. Medicine 75(1):17\u201328","journal-title":"Medicine"},{"issue":"1","key":"1596_CR89","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/MD.0b013e318205a4c6","volume":"90","author":"L Guillevin","year":"2011","unstructured":"Guillevin\u00a0L, Pagnoux\u00a0C, Seror\u00a0R, Mahr\u00a0A, Mouthon\u00a0L, Toumelin\u00a0PL et\u00a0al (2011) The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine 90(1):19\u201327","journal-title":"Medicine"},{"issue":"6","key":"1596_CR90","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1136\/annrheumdis-2012-201531","volume":"72","author":"F Moosig","year":"2013","unstructured":"Moosig\u00a0F, Bremer\u00a0JP, Hellmich\u00a0B, Holle\u00a0JU, Holl-Ulrich\u00a0K, Laudien\u00a0M et\u00a0al (2013) A\u00a0vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): monocentric experiences in 150 patients. Ann Rheum Dis 72(6):1011\u20131017","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1596_CR91","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1136\/annrheumdis-2014-206095","volume":"75","author":"AJ Mohammad","year":"2016","unstructured":"Mohammad\u00a0AJ, Hot\u00a0A, Arndt\u00a0F, Moosig\u00a0F, Guerry\u00a0MJ, Amudala\u00a0N et\u00a0al (2016) Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Ann Rheum Dis 75(2):396\u2013401","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"1596_CR92","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1136\/ard-2022-222776","volume":"81","author":"A Bettiol","year":"2022","unstructured":"Bettiol\u00a0A, Urban\u00a0ML, Bello\u00a0F, Fiori\u00a0D, Mattioli\u00a0I, Lopalco\u00a0G et\u00a0al (2022) Sequential rituximab and mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a\u00a0European multicentre observational study. Ann Rheum Dis 81(12):1769\u20131772","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1596_CR93","doi-asserted-by":"publisher","first-page":"e000905","DOI":"10.1136\/rmdopen-2019-000905","volume":"5","author":"V Teixeira","year":"2019","unstructured":"Teixeira\u00a0V, Mohammad\u00a0AJ, Jones\u00a0RB, Smith\u00a0R, Jayne\u00a0D (2019) Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis. RMD Open 5(1):e905","journal-title":"RMD Open"},{"issue":"2","key":"1596_CR94","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1002\/art.23198","volume":"58","author":"C Ribi","year":"2008","unstructured":"Ribi\u00a0C, Cohen\u00a0P, Pagnoux\u00a0C, Mahr\u00a0A, Arene\u00a0JP, Lauque\u00a0D et\u00a0al (2008) Treatment of Churg-Strauss syndrome without poor-prognosis factors: a\u00a0multicenter, prospective, randomized, open-label study of seventy-two patients. Arthritis Rheum 58(2):586\u2013594","journal-title":"Arthritis Rheum"},{"issue":"11","key":"1596_CR95","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1002\/art.40205","volume":"69","author":"X Puechal","year":"2017","unstructured":"Puechal\u00a0X, Pagnoux\u00a0C, Baron\u00a0G, Quemeneur\u00a0T, Neel\u00a0A, Agard\u00a0C et\u00a0al (2017) Adding Azathioprine to Remission-Induction Glucocorticoids for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss), Microscopic Polyangiitis, or Polyarteritis Nodosa Without Poor Prognosis Factors: A\u00a0Randomized, Controlled Trial. Arthritis Rheumatol 69(11):2175\u20132186","journal-title":"Arthritis Rheumatol"},{"issue":"20","key":"1596_CR96","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","volume":"376","author":"ME Wechsler","year":"2017","unstructured":"Wechsler\u00a0ME, Akuthota\u00a0P, Jayne\u00a0D, Khoury\u00a0P, Klion\u00a0A, Langford\u00a0CA et\u00a0al (2017) Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. N\u00a0Engl J Med 376(20):1921\u20131932","journal-title":"N Engl J Med"},{"issue":"6","key":"1596_CR97","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/acr2.11263","volume":"3","author":"I Doubelt","year":"2021","unstructured":"Doubelt\u00a0I, Cuthbertson\u00a0D, Carette\u00a0S, Chung\u00a0SA, Forbess\u00a0LJ, Khalidi\u00a0NA et\u00a0al (2021) Clinical Manifestations and Long-Term Outcomes of Eosinophilic Granulomatosis With Polyangiitis in North America. ACR Open Rheumatol 3(6):404\u2013412","journal-title":"ACR Open Rheumatol"},{"issue":"2","key":"1596_CR98","first-page":"171","volume":"38 Suppl 124","author":"I Doubelt","year":"2020","unstructured":"Doubelt\u00a0I, Pulenzas\u00a0N, Carette\u00a0S, Pagnoux\u00a0C, Canadian Vasculitis\u00a0N (2020) Efficacy of conventional immunosuppressants in relapsing or refractory eosinophilic granulomatosis with polyangiitis: evidence from a\u00a0Canadian single-centre cohort. Clin Exp Rheumatol 38 Suppl 124(2):171\u2013175","journal-title":"Clin Exp Rheumatol"},{"issue":"10","key":"1596_CR99","doi-asserted-by":"publisher","first-page":"e0185880","DOI":"10.1371\/journal.pone.0185880","volume":"12","author":"F Maritati","year":"2017","unstructured":"Maritati\u00a0F, Alberici\u00a0F, Oliva\u00a0E, Urban\u00a0ML, Palmisano\u00a0A, Santarsia\u00a0F et\u00a0al (2017) Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: A\u00a0randomised trial. PLoS ONE 12(10):e185880","journal-title":"PLoS ONE"},{"issue":"2","key":"1596_CR100","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/art.41943","volume":"74","author":"A Bettiol","year":"2022","unstructured":"Bettiol\u00a0A, Urban\u00a0ML, Dagna\u00a0L, Cottin\u00a0V, Franceschini\u00a0F, Del Giacco\u00a0S et\u00a0al (2022) Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A\u00a0European Multicenter Observational Study. Arthritis Rheumatol 74(2):295\u2013306","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"1596_CR101","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1093\/rheumatology\/ket381","volume":"53","author":"P Charles","year":"2014","unstructured":"Charles\u00a0P, Neel\u00a0A, Tieulie\u00a0N, Hot\u00a0A, Pugnet\u00a0G, Decaux\u00a0O et\u00a0al (2014) Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a\u00a0multicentre retrospective study on 80\u00a0patients. Rheumatology 53(3):532\u2013539","journal-title":"Rheumatology"},{"issue":"7","key":"1596_CR102","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1002\/art.24637","volume":"60","author":"RB Jones","year":"2009","unstructured":"Jones\u00a0RB, Ferraro\u00a0AJ, Chaudhry\u00a0AN, Brogan\u00a0P, Salama\u00a0AD, Smith\u00a0KG et\u00a0al (2009) A\u00a0multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 60(7):2156\u20132168","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1596_CR103","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/art.20718","volume":"52","author":"KA Keogh","year":"2005","unstructured":"Keogh\u00a0KA, Wylam\u00a0ME, Stone\u00a0JH, Specks\u00a0U (2005) Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52(1):262\u2013268","journal-title":"Arthritis Rheum"},{"issue":"12","key":"1596_CR104","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard-2023-224624","volume":"82","author":"A Cottu","year":"2023","unstructured":"Cottu\u00a0A, Groh\u00a0M, Desaintjean\u00a0C, Marchand-Adam\u00a0S, Guillevin\u00a0L, Puechal\u00a0X et\u00a0al (2023) Benralizumab for eosinophilic granulomatosis with polyangiitis. Ann Rheum Dis 82(12):1580\u20131586","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"1596_CR105","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1136\/ard-2023-224756","volume":"82","author":"B Molina","year":"2023","unstructured":"Molina\u00a0B, Padoan\u00a0R, Urban\u00a0ML, Novikov\u00a0P, Caminati\u00a0M, Taille\u00a0C et\u00a0al (2023) Dupilumab for relapsing or refractory sinonasal and\/or asthma manifestations in eosinophilic granulomatosis with polyangiitis: a\u00a0European retrospective study. Ann Rheum Dis 82(12):1587\u20131593","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1596_CR106","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1136\/annrheumdis-2017-211796","volume":"77","author":"JW Park","year":"2018","unstructured":"Park\u00a0JW, Curtis\u00a0JR, Moon\u00a0J, Song\u00a0YW, Kim\u00a0S, Lee\u00a0EB (2018) Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids. Ann Rheum Dis 77(5):644\u2013649","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"1596_CR107","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1136\/annrheumdis-2017-212861","volume":"77","author":"A Kronbichler","year":"2018","unstructured":"Kronbichler\u00a0A, Kerschbaum\u00a0J, Gopaluni\u00a0S, Tieu\u00a0J, Alberici\u00a0F, Jones\u00a0RB et\u00a0al (2018) Trimethoprim-sulfamethoxazole prophylaxis prevents severe\/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 77(10):1440\u20131447","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"1596_CR108","doi-asserted-by":"publisher","first-page":"1242 e11","DOI":"10.1016\/j.amjmed.2014.07.010","volume":"127","author":"P Fillatre","year":"2014","unstructured":"Fillatre\u00a0P, Decaux\u00a0O, Jouneau\u00a0S, Revest\u00a0M, Gacouin\u00a0A, Robert-Gangneux\u00a0F et\u00a0al (2014) Incidence of Pneumocystis jiroveci pneumonia among groups at risk in HIV-negative patients. Am J Med 127(12):1242 e11\u20131242 e17","journal-title":"Am J Med"},{"issue":"3 Pt 1","key":"1596_CR109","first-page":"795","volume":"151","author":"FP Ognibene","year":"1995","unstructured":"Ognibene\u00a0FP, Shelhamer\u00a0JH, Hoffman\u00a0GS, Kerr\u00a0GS, Reda\u00a0D, Fauci\u00a0AS et\u00a0al (1995) Pneumocystis carinii pneumonia: a\u00a0major complication of immunosuppressive therapy in patients with Wegener\u2019s granulomatosis. Am J Respir Crit Care Med 151(3 Pt 1):795\u2013799","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"1596_CR110","first-page":"CD005590","volume":"2014","author":"A Stern","year":"2014","unstructured":"Stern\u00a0A, Green\u00a0H, Paul\u00a0M, Vidal\u00a0L, Leibovici\u00a0L (2014) Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev 2014(10):CD5590","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"1596_CR111","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJM199503163321101","volume":"332","author":"SA Bozzette","year":"1995","unstructured":"Bozzette\u00a0SA, Finkelstein\u00a0DM, Spector\u00a0SA, Frame\u00a0P, Powderly\u00a0WG, He\u00a0W et\u00a0al (1995) A\u00a0randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N\u00a0Engl J Med 332(11):693\u2013699","journal-title":"N Engl J Med"},{"issue":"8","key":"1596_CR112","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1007\/s00296-021-04945-w","volume":"42","author":"S Jinno","year":"2022","unstructured":"Jinno\u00a0S, Akashi\u00a0K, Onishi\u00a0A, Nose\u00a0Y, Yamashita\u00a0M, Saegusa\u00a0J (2022) Comparative effectiveness of trimethoprim-sulfamethoxazole versus atovaquone for the prophylaxis of pneumocystis pneumonia in patients with connective tissue diseases receiving prolonged high-dose glucocorticoids. Rheumatol Int 42(8):1403\u20131409","journal-title":"Rheumatol Int"},{"issue":"26","key":"1596_CR113","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1056\/NEJM199812243392604","volume":"339","author":"WM El-Sadr","year":"1998","unstructured":"El-Sadr\u00a0WM, Murphy\u00a0RL, Yurik\u00a0TM, Luskin-Hawk\u00a0R, Cheung\u00a0TW, Balfour\u00a0HH Jr. et\u00a0al (1998) Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group. N\u00a0Engl J Med 339(26):1889\u20131895","journal-title":"N Engl J Med"},{"issue":"7","key":"1596_CR114","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1055\/a-1498-2512","volume":"59","author":"MSL Cornberg","year":"2021","unstructured":"Cornberg\u00a0MSL, Protzer\u00a0U, Niederau\u00a0C, Tacke\u00a0F, Berg\u00a0T, Glebe\u00a0D, Jilg\u00a0W, Wedemeyer\u00a0H, Wirth\u00a0S, H\u00f6ner Zu Siederdissen\u00a0C, Lynen-Jansen\u00a0P, van Leeuwen\u00a0P, Petersen\u00a0J, Collaborators (2021) S3-Leitlinie der Deutschen Gesellschaft f\u00fcr Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion \u2013 (AWMF-Register-Nr. 021-11). Z\u00a0Gastroenterol 59(7):691\u2013776","journal-title":"Z Gastroenterol"},{"issue":"1","key":"1596_CR115","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","volume":"79","author":"V Furer","year":"2020","unstructured":"Furer\u00a0V, Rondaan\u00a0C, Heijstek\u00a0MW, Agmon-Levin\u00a0N, van Assen\u00a0S, Bijl\u00a0M et\u00a0al (2020) 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 79(1):39\u201352","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"1596_CR116","doi-asserted-by":"crossref","first-page":"690-4","DOI":"10.1007\/s00393-013-1155-4","volume":"72","author":"S Goldacker","year":"2013","unstructured":"Goldacker\u00a0S, Gause\u00a0AM, Warnatz\u00a0K, der Kommission Pharmakotherapie\u00a0D (2013) Vaccination in adult patients with chronic inflammatory rheumatic diseases. Z\u00a0Rheumatol 72(7):690-4\u2013700\u20116","journal-title":"Z Rheumatol"},{"issue":"7","key":"1596_CR117","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00393-013-1154-5","volume":"72","author":"K Warnatz","year":"2013","unstructured":"Warnatz\u00a0K, Goldacker\u00a0S, Gause\u00a0AM, der die Kommission Pharmakotherapie\u00a0D (2013) Vaccination recommendations of the Commission for Pharmacotherapy of the German Society of Rheumatology. Z\u00a0Rheumatol 72(7):687\u2013689","journal-title":"Z Rheumatol"},{"issue":"8","key":"1596_CR118","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1002\/art.30427","volume":"63","author":"D Tesfa","year":"2011","unstructured":"Tesfa\u00a0D, Ajeganova\u00a0S, Hagglund\u00a0H, Sander\u00a0B, Fadeel\u00a0B, Hafstrom\u00a0I et\u00a0al (2011) Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum 63(8):2209\u20132214","journal-title":"Arthritis Rheum"},{"issue":"6","key":"1596_CR119","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1136\/ard.2009.109389","volume":"69","author":"MA Little","year":"2010","unstructured":"Little\u00a0MA, Nightingale\u00a0P, Verburgh\u00a0CA, Hauser\u00a0T, De Groot\u00a0K, Savage\u00a0C et\u00a0al (2010) Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis 69(6):1036\u20131043","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"1596_CR120","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1002\/eji.202048713","volume":"50","author":"L Hanitsch","year":"2020","unstructured":"Hanitsch\u00a0L, Baumann\u00a0U, Boztug\u00a0K, Burkhard-Meier\u00a0U, Fasshauer\u00a0M, Habermehl\u00a0P et\u00a0al (2020) Treatment and management of primary antibody deficiency: German interdisciplinary evidence-based consensus guideline. Eur J Immunol 50(10):1432\u20131446","journal-title":"Eur J Immunol"},{"issue":"2","key":"1596_CR121","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00393-021-01025-z","volume":"80","author":"J Leipe","year":"2021","unstructured":"Leipe\u00a0J, Holle\u00a0JU, Weseloh\u00a0C, Pfeil\u00a0A, Kruger\u00a0K (2021) German Society of Rheumatology recommendations for management of glucocorticoid-induced osteoporosis. Z\u00a0Rheumatol 80(2):49\u201363","journal-title":"Z Rheumatol"},{"issue":"10","key":"1596_CR122","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1136\/ard.2003.019125","volume":"63","author":"A Knight","year":"2004","unstructured":"Knight\u00a0A, Askling\u00a0J, Granath\u00a0F, Sparen\u00a0P, Ekbom\u00a0A (2004) Urinary bladder cancer in Wegener\u2019s granulomatosis: risks and relation to cyclophosphamide. Ann Rheum Dis 63(10):1307\u20131311","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1596_CR123","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/acr.20116","volume":"62","author":"M Faurschou","year":"2010","unstructured":"Faurschou\u00a0M, Dreyer\u00a0L, Kamper\u00a0AL, Starklint\u00a0H, Jacobsen\u00a0S (2010) Long-term mortality and renal outcome in a\u00a0cohort of 100 patients with lupus nephritis. Arthritis Care Res 62(6):873\u2013880","journal-title":"Arthritis Care Res"},{"issue":"1","key":"1596_CR124","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/art.25061","volume":"62","author":"PA Monach","year":"2010","unstructured":"Monach\u00a0PA, Arnold\u00a0LM, Merkel\u00a0PA (2010) Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a\u00a0data-driven review. Arthritis Rheum 62(1):9\u201321","journal-title":"Arthritis Rheum"},{"issue":"7","key":"1596_CR125","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1093\/jnci\/87.7.524","volume":"87","author":"LB Travis","year":"1995","unstructured":"Travis\u00a0LB, Curtis\u00a0RE, Glimelius\u00a0B, Holowaty\u00a0EJ, Van Leeuwen\u00a0FE, Lynch\u00a0CF et\u00a0al (1995) Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin\u2019s lymphoma. J\u00a0Natl Cancer Inst 87(7):524\u2013530","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"1596_CR126","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1136\/annrheumdis-2016-209925","volume":"76","author":"EE van Daalen","year":"2017","unstructured":"van Daalen\u00a0EE, Rizzo\u00a0R, Kronbichler\u00a0A, Wolterbeek\u00a0R, Bruijn\u00a0JA, Jayne\u00a0DR et\u00a0al (2017) Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis. Ann Rheum Dis 76(6):1064\u20131069","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1596_CR127","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/ijc.10444","volume":"100","author":"A Knight","year":"2002","unstructured":"Knight\u00a0A, Askling\u00a0J, Ekbom\u00a0A (2002) Cancer incidence in a\u00a0population-based cohort of patients with Wegener\u2019s granulomatosis. Int J Cancer 100(1):82\u201385","journal-title":"Int J Cancer"},{"issue":"8","key":"1596_CR128","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1136\/ard.2010.145250","volume":"70","author":"C Heijl","year":"2011","unstructured":"Heijl\u00a0C, Harper\u00a0L, Flossmann\u00a0O, Stucker\u00a0I, Scott\u00a0DG, Watts\u00a0RA et\u00a0al (2011) Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials. Ann Rheum Dis 70(8):1415\u20131421","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1596_CR129","first-page":"100","volume":"35","author":"M Faurschou","year":"2008","unstructured":"Faurschou\u00a0M, Sorensen\u00a0IJ, Mellemkjaer\u00a0L, Loft\u00a0AG, Thomsen\u00a0BS, Tvede\u00a0N et\u00a0al (2008) Malignancies in Wegener\u2019s granulomatosis: incidence and relation to cyclophosphamide therapy in a\u00a0cohort of 293 patients. J\u00a0Rheumatol 35(1):100\u2013105","journal-title":"J Rheumatol"},{"issue":"5","key":"1596_CR130","doi-asserted-by":"publisher","first-page":"477","DOI":"10.7326\/0003-4819-124-5-199603010-00003","volume":"124","author":"C Talar-Williams","year":"1996","unstructured":"Talar-Williams\u00a0C, Hijazi\u00a0YM, Walther\u00a0MM, Linehan\u00a0WM, Hallahan\u00a0CW, Lubensky\u00a0I et\u00a0al (1996) Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 124(5):477\u2013484","journal-title":"Ann Intern Med"},{"issue":"10","key":"1596_CR131","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1136\/ard.2004.023937","volume":"63","author":"B Hellmich","year":"2004","unstructured":"Hellmich\u00a0B, Kausch\u00a0I, Doehn\u00a0C, Jocham\u00a0D, Holl-Ulrich\u00a0K, Gross\u00a0WL (2004) Urinary bladder cancer in Wegener\u2019s granulomatosis: is it more than cyclophosphamide? Ann Rheum Dis 63(10):1183\u20131185","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1596_CR132","doi-asserted-by":"publisher","first-page":"488","DOI":"10.7326\/0003-4819-116-6-488","volume":"116","author":"GS Hoffman","year":"1992","unstructured":"Hoffman\u00a0GS, Kerr\u00a0GS, Leavitt\u00a0RY, Hallahan\u00a0CW, Lebovics\u00a0RS, Travis\u00a0WD et\u00a0al (1992) Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 116(6):488\u2013498","journal-title":"Ann Intern Med"},{"issue":"5","key":"1596_CR133","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1002\/1529-0131(200005)43:5<1021::AID-ANR10>3.0.CO;2-J","volume":"43","author":"E Reinhold-Keller","year":"2000","unstructured":"Reinhold-Keller\u00a0E, Beuge\u00a0N, Latza\u00a0U, de Groot\u00a0K, Rudert\u00a0H, Nolle\u00a0B et\u00a0al (2000) An interdisciplinary approach to the care of patients with Wegener\u2019s granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 43(5):1021\u20131032","journal-title":"Arthritis Rheum"},{"issue":"12","key":"1596_CR134","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1002\/acr.20605","volume":"63","author":"ME Clowse","year":"2011","unstructured":"Clowse\u00a0ME, Copland\u00a0SC, Hsieh\u00a0TC, Chow\u00a0SC, Hoffman\u00a0GS, Merkel\u00a0PA et\u00a0al (2011) Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener\u2019s). Arthritis Care Res 63(12):1777\u20131781","journal-title":"Arthritis Care Res"},{"issue":"1 Suppl 70","key":"1596_CR135","first-page":"S53","volume":"30","author":"JC Henes","year":"2012","unstructured":"Henes\u00a0JC, Henes\u00a0M, von Wolff\u00a0M, Schmalzing\u00a0M, Kotter\u00a0I, Lawrenz\u00a0B (2012) Fertility preservation in women with vasculitis: experiences from the FertiPROTEKT network. Clin Exp Rheumatol 30(1 Suppl 70):S53\u2013S56","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"1596_CR136","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1093\/rheumatology\/keac551","volume":"62","author":"MD Russell","year":"2023","unstructured":"Russell\u00a0MD, Dey\u00a0M, Flint\u00a0J, Davie\u00a0P, Allen\u00a0A, Crossley\u00a0A et\u00a0al (2023) British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids. Rheumatology 62(4):e48\u2013e88","journal-title":"Rheumatology"},{"issue":"5","key":"1596_CR137","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1136\/annrheumdis-2015-208840","volume":"75","author":"C Gotestam Skorpen","year":"2016","unstructured":"Gotestam Skorpen\u00a0C, Hoeltzenbein\u00a0M, Tincani\u00a0A, Fischer-Betz\u00a0R, Elefant\u00a0E, Chambers\u00a0C et\u00a0al (2016) The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 75(5):795\u2013810","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"1596_CR138","doi-asserted-by":"publisher","first-page":"3270","DOI":"10.1002\/art.39317","volume":"67","author":"C Rahmattulla","year":"2015","unstructured":"Rahmattulla\u00a0C, Berden\u00a0AE, Wakker\u00a0SC, Reinders\u00a0ME, Hagen\u00a0EC, Wolterbeek\u00a0R et\u00a0al (2015) Incidence of Malignancies in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Diagnosed Between 1991 and 2013. Arthritis Rheumatol 67(12):3270\u20133278","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"1596_CR139","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.3899\/jrheum.181438","volume":"47","author":"C Heijl","year":"2020","unstructured":"Heijl\u00a0C, Westman\u00a0K, Hoglund\u00a0P, Mohammad\u00a0AJ (2020) Malignancies in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitis: A\u00a0Population-based Cohort Study. J\u00a0Rheumatol 47(8):1229\u20131237","journal-title":"J Rheumatol"},{"issue":"1","key":"1596_CR140","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1136\/annrheumdis-2013-203927","volume":"74","author":"J Robson","year":"2015","unstructured":"Robson\u00a0J, Doll\u00a0H, Suppiah\u00a0R, Flossmann\u00a0O, Harper\u00a0L, Hoglund\u00a0P et\u00a0al (2015) Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials. Ann Rheum Dis 74(1):177\u2013184","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"1596_CR141","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1002\/art.21117","volume":"52","author":"P Seo","year":"2005","unstructured":"Seo\u00a0P, Min\u00a0YI, Holbrook\u00a0JT, Hoffman\u00a0GS, Merkel\u00a0PA, Spiera\u00a0R et\u00a0al (2005) Damage caused by Wegener\u2019s granulomatosis and its treatment: prospective data from the Wegener\u2019s Granulomatosis Etanercept Trial (WGET). Arthritis Rheum 52(7):2168\u20132178","journal-title":"Arthritis Rheum"},{"issue":"3","key":"1596_CR142","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1136\/ard.2010.137778","volume":"70","author":"O Flossmann","year":"2011","unstructured":"Flossmann\u00a0O, Berden\u00a0A, de Groot\u00a0K, Hagen\u00a0C, Harper\u00a0L, Heijl\u00a0C et\u00a0al (2011) Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 70(3):488\u2013494","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"1596_CR143","doi-asserted-by":"publisher","first-page":"3493","DOI":"10.1002\/art.24957","volume":"60","author":"MD Morgan","year":"2009","unstructured":"Morgan\u00a0MD, Turnbull\u00a0J, Selamet\u00a0U, Kaur-Hayer\u00a0M, Nightingale\u00a0P, Ferro\u00a0CJ et\u00a0al (2009) Increased incidence of cardiovascular events in patients with antineutrophil cytoplasmic antibody-associated vasculitides: a\u00a0matched-pair cohort study. Arthritis Rheum 60(11):3493\u20133500","journal-title":"Arthritis Rheum"},{"issue":"4","key":"1596_CR144","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1136\/ard.2008.099051","volume":"68","author":"Y Allenbach","year":"2009","unstructured":"Allenbach\u00a0Y, Seror\u00a0R, Pagnoux\u00a0C, Teixeira\u00a0L, Guilpain\u00a0P, Guillevin\u00a0L et\u00a0al (2009) High frequency of venous thromboembolic events in Churg-Strauss syndrome, Wegener\u2019s granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a\u00a0systematic retrospective study on 1130 patients. Ann Rheum Dis 68(4):564\u2013567","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1596_CR145","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1093\/rheumatology\/ken035","volume":"47","author":"PM Stassen","year":"2008","unstructured":"Stassen\u00a0PM, Derks\u00a0RP, Kallenberg\u00a0CG, Stegeman\u00a0CA (2008) Venous thromboembolism in ANCA-associated vasculitis\u2014incidence and risk factors. Rheumatology 47(4):530\u2013534","journal-title":"Rheumatology"},{"issue":"8","key":"1596_CR146","doi-asserted-by":"publisher","first-page":"620","DOI":"10.7326\/0003-4819-142-8-200505030-00011","volume":"142","author":"PA Merkel","year":"2005","unstructured":"Merkel\u00a0PA, Lo\u00a0GH, Holbrook\u00a0JT, Tibbs\u00a0AK, Allen\u00a0NB, Davis\u00a0JC Jr. et\u00a0al (2005) Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener\u2019s Clinical Occurrence of Thrombosis (WeCLOT) Study. Ann Intern Med 142(8):620\u2013626","journal-title":"Ann Intern Med"},{"issue":"6","key":"1596_CR147","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1136\/annrheumdis-2021-221733","volume":"81","author":"GC Drosos","year":"2022","unstructured":"Drosos\u00a0GC, Vedder\u00a0D, Houben\u00a0E, Boekel\u00a0L, Atzeni\u00a0F, Badreh\u00a0S et\u00a0al (2022) EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis 81(6):768\u2013779","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1596_CR148","doi-asserted-by":"publisher","first-page":"v5","DOI":"10.1093\/ndt\/gfg1033","volume":"18","author":"S Kaplan-Pavlovcic","year":"2003","unstructured":"Kaplan-Pavlovcic\u00a0S, Cerk\u00a0K, Kveder\u00a0R, Lindic\u00a0J, Vizjak\u00a0A (2003) Clinical prognostic factors of renal outcome in anti-neutrophil cytoplasmic autoantibody (ANCA)-associated glomerulonephritis in elderly patients. Nephrol Dial Transplant 18(5):v5\u2013v7","journal-title":"Nephrol Dial Transplant"},{"issue":"4S","key":"1596_CR149","first-page":"S1","volume":"100","author":"Kidney Disease: Improving Global Outcomes Glomerular Diseases Work G","year":"2021","unstructured":"Kidney Disease: Improving Global Outcomes Glomerular Diseases Work G (2021) KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int 100(4S):S1\u2013S276","journal-title":"Kidney Int"},{"issue":"12","key":"1596_CR150","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1097\/TP.0b013e31821ab9aa","volume":"91","author":"D Geetha","year":"2011","unstructured":"Geetha\u00a0D, Eirin\u00a0A, True\u00a0K, Irazabal\u00a0VM, Specks\u00a0U, Seo\u00a0P et\u00a0al (2011) Renal transplantation in antineutrophil cytoplasmic antibody-associated vasculitis: a\u00a0multicenter experience. Transplantation 91(12):1370\u20131375","journal-title":"Transplantation"},{"issue":"2","key":"1596_CR151","first-page":"115","volume":"36 Suppl 111","author":"ES Park","year":"2018","unstructured":"Park\u00a0ES, Ahn\u00a0SS, Jung\u00a0SM, Song\u00a0JJ, Park\u00a0YB, Lee\u00a0SW (2018) Renal outcome of kidney-transplantation in Korean recipients with ANCA-associated vasculitis. Clin Exp Rheumatol 36 Suppl 111(2):115\u2013120","journal-title":"Clin Exp Rheumatol"},{"issue":"11","key":"1596_CR152","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1002\/acr.20276","volume":"62","author":"K Herlyn","year":"2010","unstructured":"Herlyn\u00a0K, Hellmich\u00a0B, Seo\u00a0P, Merkel\u00a0PA (2010) Patient-reported outcome assessment in vasculitis may provide important data and a\u00a0unique perspective. Arthritis Care Res 62(11):1639\u20131645","journal-title":"Arthritis Care Res"},{"issue":"8","key":"1596_CR153","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1093\/rheumatology\/keu026","volume":"53","author":"J Mooney","year":"2014","unstructured":"Mooney\u00a0J, Spalding\u00a0N, Poland\u00a0F, Grayson\u00a0P, Leduc\u00a0R, McAlear\u00a0CA et\u00a0al (2014) The informational needs of patients with ANCA-associated vasculitis-development of an informational needs questionnaire. Rheumatology 53(8):1414\u20131421","journal-title":"Rheumatology"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-024-01596-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-024-01596-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-024-01596-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T12:31:16Z","timestamp":1743856276000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-024-01596-7"}},"subtitle":["KURZVERSION der S3-Leitlinie der Deutschen Gesellschaft f\u00fcr Rheumatologie und Klinische Immunologie e.\u202fV. (DGRh) und Deutschen Gesellschaft f\u00fcr Innere Medizin e.\u202fV. (DGIM), Deutschen Gesellschaft f\u00fcr Nephrologie e.\u202fV. (DGfN), Deutschen Gesellschaft f\u00fcr HNO-Heilkunde und Kopf-Hals-Chirurgie e.\u202fV. (DGHNO-KHC), Deutschen Ophthalmologischen Gesellschaft e.\u202fV. (DOG), Deutschen Gesellschaft f\u00fcr Neurologie e.\u202fV. (DGN), Deutschen Gesellschaft f\u00fcr Pneumologie und Beatmungsmedizin e.\u202fV. (DGP), Deutschen Gesellschaft f\u00fcr Pathologie e.\u202fV. (DGP), Deutschen R\u00f6ntgengesellschaft, Gesellschaft f\u00fcr Medizinische Radiologie e.\u202fV. (DRG), Bundesverband Deutscher Pathologen, Bundesverband Niere e.\u202fV., Deutschen Rheuma-Liga Bundesverband e.\u202fV.","SHORT VERSION of the S3 guideline of the German Society for Rheumatology and Clinical Immunology e.\u202fV. (DGRh) and German Society for Internal Medicine e.\u202fV. (DGIM), German Society for Nephrology e.\u202fV. (DGfN), German Society for Otorhinolaryngology and Head and Neck Surgery e.\u202fV. (DGHNO-KHC), German Ophthalmological Society e.\u202fV. (DOG), German Society for Neurology e.\u202fV. (DGN), German Society for Pneumology and Respiratory Medicine e.\u202fV. (DGP), German Society for Pathology e.\u202fV. (DGP), German Radiological Society, Society for Medical Radiology e.\u202fV. (DRG), Federal Association of German Pathologists, Federal Kidney Association e.\u202fV., German Rheumatism League Federal Association e.\u202fV."],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":153,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1596"],"URL":"https:\/\/doi.org\/10.1007\/s00393-024-01596-7","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"21 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Die Darlegung der Interessenkonflikte ist im Leitlinienreport zu dieser Leitlinie einsehbar.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}